Temsirolimus (CCI-779): Early results of an mTOR inhibitor in renal carcinoma

被引：0
|
作者：
Hudes, GR [1 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [41] Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Vij, Ravi
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Laubach, Jacob
    Campagnaro, Erica L.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Dollard, Akari M.
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    [J]. BLOOD, 2009, 114 (22) : 311 - 312
  • [42] Targeting mTOR by CCI-779 lowers HIF levels and reduces survival advantage of VHL renal cell cancers in preclinical studies
    不详
    [J]. CANCER BIOLOGY & THERAPY, 2006, 5 (02) : 7 - 7
  • [43] Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
    Galanis, E
    Buckner, JC
    Maurer, MJ
    Kreisberg, JL
    Ballman, K
    Boni, J
    Peralba, JM
    Jenkins, RB
    Dakhil, SR
    Morton, RF
    Jaeckle, KA
    Scheithauer, BW
    Dancey, J
    Hidalgo, M
    Walsh, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5294 - 5304
  • [44] Pharmacokinetic profile of temsirolimus (CCI-779) iv with concomitant administration of cytochrome P450-inducing medications.
    Boni, J. P.
    Leister, C.
    Burns, J.
    Cincotta, M.
    Hug, B.
    Moore, L.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S76 - S76
  • [45] Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma
    Malizzia, Lois J.
    Hsu, Arlene
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (04) : 639 - 646
  • [46] Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
    Smith, S. M.
    Pro, B.
    Cisneros, A.
    Smith, S.
    Stiff, P.
    Lester, E.
    Modi, S.
    Dancey, J. E.
    Vokes, E. E.
    van Besien, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
    Ansell, Stephen M.
    Tang, Hui
    Kurtin, Paul
    Koenig, Patricia
    Inwards, David J.
    Shah, Keith
    Witzig, Thomas E.
    [J]. BLOOD, 2009, 114 (22) : 664 - 665
  • [48] Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
    Robins, H. I.
    Wen, P. Y.
    Chang, S. M.
    Kuhn, J.
    Lamborn, K.
    Cloughesy, T.
    Glibert, M. R.
    Yung, W. K.
    Dancey, J.
    Prados, M. D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] A phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor.
    Hidalgo, M
    Rowinsky, E
    Erlichman, C
    Drengler, R
    Marshall, B
    Marks, R
    Edwards, T
    Boni, J
    Dukart, G
    Buckner, J
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 133 - 133
  • [50] PHASE I/II STUDY OF ERLOTINIB AND CCI-779 (TEMSIROLIMUS) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMAS (NABTC 04-02)
    Wen, Patrick
    Chang, Susan
    Kuhn, John
    Lamborn, Kathleen
    Robins, H. Ian
    Yung, Alfred
    Gilbert, Mark R.
    Cloughesy, Timothy
    Lieberman, Frank
    DeAngelis, Lisa
    Abrey, Lauren
    Drappatz, Jan
    Kesari, Santosh
    Dancey, Janet
    Prados, Michel D.
    [J]. NEURO-ONCOLOGY, 2009, 11 (02) : 232 - 232
12345